Louise A A Gerbens
Overview
Explore the profile of Louise A A Gerbens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bosma A, Gerbens L, El Khattabi H, Loeff F, Duckworth M, Woolf R, et al.
J Dermatolog Treat
. 2023 Apr;
34(1):2193663.
PMID: 37098906
Background: Dupilumab is prescribed in one dosage across adult atopic dermatitis patients. Differences in drug exposure may explain variation in treatment response. Objective: Investigating the clinical relevance of dupilumab serum...
12.
Bosma A, Ouwerkerk W, Heidema M, Prieto-Merino D, Ardern-Jones M, Beattie P, et al.
JAAD Int
. 2022 Nov;
10:14-24.
PMID: 36387062
Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and...
13.
Rick J, Gould L, Marzano A, Garg A, Chen D, Oakes D, et al.
Arch Dermatol Res
. 2022 Oct;
315(4):983-988.
PMID: 36305958
Introduction: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that affects approximately 0.3-6 out of every 100,000 people worldwide. Clinical trials are scarce but there is growing interest in using...
14.
Leshem Y, Chalmers J, Apfelbacher C, Katoh N, Gerbens L, Schmitt J, et al.
JAMA Dermatol
. 2022 Oct;
158(12):1429-1435.
PMID: 36223090
Importance: Measuring outcomes in clinical practice can aid patient care, quality improvement, and real-world evidence generation. The Harmonising Outcome Measures for Eczema (HOME) Clinical Practice initiative is developing a list...
15.
Bosma A, Musters A, Bloem M, Gerbens L, Middelkamp-Hup M, Haufe E, et al.
J Eur Acad Dermatol Venereol
. 2022 Aug;
37(1):123-136.
PMID: 36018221
Background: The TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative international network of registries collecting data of atopic eczema (AE) patients receiving systemic and phototherapy with the common...
16.
Williams H, Schmitt J, Thomas K, Spuls P, Simpson E, Apfelbacher C, et al.
J Allergy Clin Immunol
. 2022 Mar;
149(6):1899-1911.
PMID: 35351441
Core outcome sets are critically important outcomes that should be measured in clinical trials. Their absence in atopic dermatitis is a form of research waste and impedes combining evidence to...
17.
van Huizen A, Vermeulen F, Bik C, Borgonjen R, Karsch S, Kuin R, et al.
J Dermatolog Treat
. 2021 Aug;
33(4):1947-1966.
PMID: 34425719
If an authorized drug is prescribed for a use that is not described in the Summary of Product Characteristics, this is defined as 'off-label use.' Methotrexate is often used off-label...
18.
Bosma A, Ouwerkerk W, Gunal M, Hyseni A, Arents B, Gerbens L, et al.
J Dermatol
. 2021 May;
48(9):1305-1314.
PMID: 34013539
Atopic dermatitis is associated with work productivity loss. Little is known about how patients perceive their work ability and quality of working life, and how this is affected by treatment....
19.
Bosma A, de Wijs L, Hof M, van Nieuwenhuizen B, Gerbens L, Middelkamp-Hup M, et al.
J Am Acad Dermatol
. 2021 Mar;
85(3):e173-e174.
PMID: 33675862
No abstract available.
20.
Bosma A, de Wijs L, Hof M, van Nieuwenhuizen B, Gerbens L, Middelkamp-Hup M, et al.
J Am Acad Dermatol
. 2020 Jun;
83(5):1375-1384.
PMID: 32485210
Background: Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. Objective: To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of...